Several studies reported that EphA2 is selectively upregulated in diverse arrays of cancer including, but not limited to, breast, pancreas, prostate, lung, and most importantly ovarian cancer affecting cancerous cells growth, invasion, and metastasis and angiogenesis and increasing the tumor burden. Here, EPHA2 is linked to neoplasm.